TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged ≥50 years who signed the informed consent~Exclusion Criteria:~* history of S. pneumoniae infection within the previous 5 years~* previous pneumococcal vaccination~* previous tetanus-diphtheria (Td) vaccination within the last 10 years~* known immunodeficiency or immunosuppressant use or coagulation disorders

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Tetanus-diphtheria (Td) and PCV13 (Type: ACTIVE_COMPARATOR): None
- PCV13 alone (Type: ACTIVE_COMPARATOR): None
- Td alone (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Trial of 4% Nebulized Lignocaine vs. 10% Lignocaine Spray in Patients Undergoing Flexible Bronchoscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Willing for flexible bronchoscopy procedure a~Exclusion Criteria:~* Requirement of intravenous sedation to undergo any procedure including EBUS-TBNA, conventional TBNA, radial EBUS procedure and interventional pulmonary procedures~* Sensitivity to lignocaine~* Hemodynamically unstable patients (SBP \< 90 mm Hg)~* Baseline hypoxemia (SpO2 \<92% on room air)~* Pregnancy~* Comorbid illness such as heart failure, CKD, chronic liver disease and others~* Failure to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Nebulized lignocaine (Type: EXPERIMENTAL): 2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
- Lignocaine spray (Type: EXPERIMENTAL): 10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
- Combined spray and nebulization (Type: ACTIVE_COMPARATOR): Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ATLAS: Ambulatory Treatments for Leakage Associated With Stress

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Stress urinary incontinence or stress-predominant mixed urinary incontinence, with at least 2 episodes of stress incontinence on 7-day bladder diary and the number of stress incontinence episodes exceeding the number of urge incontinence episodes.~* Urinary incontinence for at least three months.~* Ambulatory adult women.~* Stage 0-I-II pelvic organ prolapse.~Exclusion Criteria:~* Continual urine leakage.~* Pregnancy or planning pregnancy within 1 year.~* Active urinary tract infection.~* Urinary retention.~* Currently on medication for incontinence.~* Currently using a pessary.~* Neurologic condition that affects bladder function.

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intravaginal Pessary (Type: EXPERIMENTAL): Pessary restores continence by stabilization of the proximal urethra and urethrovesical junction, facilitating pressure transmission to the proximal urethra.
- Behavioral Therapy (Type: EXPERIMENTAL): Pelvic floor muscle training and exercise which includes strong contraction of the pelvic floor muscles to prevent incontinence by occluding the urethra and regular practice can improve pelvic muscle support.
- Pessary combined with behavioral therapy (Type: EXPERIMENTAL): Combination of the explanations above.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained~* Body Mass Index (BMI) of 30.0 kg/m\^2 or above~* Body Mass Index (BMI) of 27 kg/m\^2 or above in the presence of co-morbidities of treated or untreated dyslipidemia and/or hypertension~* Stable body weight~* Preceding failed dietary effort~Exclusion Criteria:~* Known type 1 or type 2 diabetes~* Glycosylated haemoglobin (HbA1c) of 6.5 % or above (Screening visit 1) or FPG of 126 mg/dL (7 mmol/L) or above (Screening visit 2) or 2 hour post-challenge (OGTT) plasma glucose of 200 mg/dL (11.1 mmol/L) or above (Screening visit 2)~* Screening calcitonin of 50 ng/L or above~* Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)~* Personal history of non-familial medullary thyroid carcinoma~* History of acute or chronic pancreatitis~* Obesity induced by drug treatment~* Use of approved weight lowering pharmacotherapy~* Previous surgical treatment of obesity~* History of major depressive disorder or suicide attempt~* Uncontrolled hypertension (systolic blood pressure of 160 mmHg or above and/or diastolic blood pressure of 100 mmHg or above)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) (Type: EXPERIMENTAL): None
- Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68) (Type: EXPERIMENTAL): None
- Liraglutide Placebo, no Pre-diabetes (Type: PLACEBO_COMPARATOR): None
- Liraglutide 3.0mg, Pre-diabetes (Type: EXPERIMENTAL): None
- Liraglutide Placebo, Pre-diabetes (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have had seasonal allergic rhinitis due to Ragweed for the last 2 consecutive years~* Subjects who obtain a minimum sum score, considering Seasonal Allergic Rhinitis (SAR) related symptoms (mean value), as defined by the protocol~Exclusion Criteria:~* Any clinically significant condition that might interfere with the treatment evaluation, both for efficacy and safety~* Have used forbidden concomitant medications as defined by the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (PBO) (Type: PLACEBO_COMPARATOR): Placebo was administered orally on Days 1 and 2.
- Montelukast (MLKT) (Type: EXPERIMENTAL): 10 mg of Montelukast (MLKT) was administered orally on Days 1 and 2.
- Levocetirizine (LCTZ) (Type: EXPERIMENTAL): 5 mg of Levocetirizine (LCTZ) was administered orally on Days 1 and 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy (POD1UM-202)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to comprehend and willingness to sign a written informed consent form.~* Confirmed diagnosis of locally advanced or metastatic SCAC.~* Must have received (or been intolerant to or ineligible for) at least 1 prior line of platinum-based chemotherapy and received no more than 2 prior systemic treatments.~* Must have measurable disease by RECIST v1.1.~* Eastern Cooperative Oncology Group performance status of 0 to 1.~* If HIV-positive, then all of the following criteria must also be met: CD4+ count ≥ 300/μL, undetectable viral load, and receiving highly active antiretroviral therapy.~Exclusion Criteria:~* Receipt of anticancer therapy or participation in another interventional clinical study within 21 days before the first administration of study drug; 6 weeks for mitomycin C.~* Radiotherapy within 14 days of first dose of study treatment with the following caveats: 28 days for pelvic radiotherapy, 6 months for thoracic region radiotherapy that is \> 30 Gy.~* Prior treatment with programmed cell death protein 1 (PD-1) or programmed cell death ligand protein 1 (PD-L1)-directed therapy.~* Active autoimmune disease requiring systemic immunosuppression.~* Known central nervous system (CNS) metastases and/or carcinomatous meningitis.~* Known active hepatitis infection.~* Active infections requiring systemic therapy.~* Is pregnant or breastfeeding or is expecting to conceive or father children within the projected duration of the study, from screening through 6 months after the last dose of study drug.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Retifanlimab 500 mg (Type: EXPERIMENTAL): Retifanlimab 500 milligrams (mg) intravenously every 4 weeks (Q4W).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Augmented Care at Worksite for Diabetes Prevention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Benefits-eligible Ohio State University (OSU) employee~2. Intend to be employed by OSU through the length of the follow-up phase~3. Body mass index: \>24 kg/m\^2 non-Asians; \>22 kg/m\^2 Asians~4. Fasting blood glucose of 100-125 mg/dL or an A1c of 5.7-6.4%~5. Blood glucose of 110-199 (if non-fasting in previous 2 hours)~Exclusion Criteria:~1. Blood glucose level of ≥ 200 mg/dL~2. Conditions that would limit adoption of light/moderate physical activity (i.e., cardiac event, severe chronic obstructive pulmonary disease, advanced arthritis, poorly controlled hypertension)~3. Chronic use of medications that affect blood glucose levels (i.e., corticosteroids)~4. Concurrent participation in a structured weight loss program or counseling for bariatric surgery~5. Pregnant or breastfeeding~6. Score of ≥ 10 on the Patient Health Questionnaire-8 indicating moderate to severe depressive symptoms~7. Score of ≥ 27 on the Binge Eating Scale indicating the potential for binge eating~8. Unwilling to accept randomization~9. Planning to move from the area or changing employment.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group Lifestyle Balance (GLB) (Type: ACTIVE_COMPARATOR): Standard lifestyle intervention to promote weight loss
- Group Lifestyle Balance Plus (GLB+) (Type: EXPERIMENTAL): Augmented lifestyle intervention for early slow responders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: German Adaptation of REACH II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* age 21 years or older~* living with or sharing cooking facilities with the care recipient~* providing care for a relative with a medical diagnosed Alzheimer disease or related disorder, vascular dementia or behavior variant frontotemporal dementia for at least 4 hours per day for at least the past 6 months~Exclusion criteria~* Involvment in another caregiver intervention~* actual psychiatric diagnosis of mental illness~* illness that would prevent 6 months of study participation~* forthcoming institutionalization of the person being cared.~Other requirements were logistic, including having a telephone, planning to remain in the geographic area for at least 6 months, and competency in German.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GE-REACH-program (Type: EXPERIMENTAL): GE-REACH-program
- control group (Type: NO_INTERVENTION): usual care

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Monotherapy With Levetiracetam in Newly Diagnosed Patients Suffering From Epilepsy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects with newly or recently diagnosed epilepsy having experienced unprovoked partial seizures (IA, IB, IC with clear focal origin), or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures. The discrimination between IC and IIE is not requested for inclusion.~* Subjects with at least 2 unprovoked seizures separated by a minimum of 48 hours in the year preceding randomization out of which at least 1 unprovoked seizure in the 3 months preceding randomization.~* Subjects with a confirmed diagnosis of epilepsy.~* Male/female subjects (≥16 years).~Exclusion Criteria:~* History or presence of seizures of other types than partial (IA, IB, IC, with clear focal origin) and generalized tonic-clonic (without clear focal origin) seizures.~* History or presence of seizures occurring only in clustered patterns, defined as repeated seizures occurring over a short period of time, i.e. \< 20 minutes, with or without function regained between 2 ictal events.~* History, clinical or EEG finding suggestive of idiopathic generalized epilepsy (IGE) at randomization.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Erectile Dysfunction II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male, at least 19 years of age~* Stable monogamous relationship for at least 6 months with a consenting female partner who is at least 19 years of age, vaginal intercourse is a required study activity~* History of ED (clinically defined as the inability to attain and maintain an erection of the penis sufficient to permit satisfactory sexual intercourse) of at least 3 months duration~* Partner is not pregnant or lactating~Exclusion Criteria:~* History of new-onset symptomatic coronary artery disease within the last 3 months or a history of myocardial infarction or cardiac surgical procedure within six months~* Cardiac arrhythmias requiring antiarrhythmic treatment~* Symptomatic congestive heart failure~* Taking nitrate medication in any form~* Uncontrolled diabetes (HbA1c ≥ 13%)~* Hypersensitivity to phosphodiesterase type 5 (PDE-5) inhibitors such as Viagra®, Cialis® or Levitra®~* Previously failed to respond to PDE-5 inhibitors such as Viagra®, Cialis® or Levitra®

- Gender: MALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Udenafil 50 mg (Type: EXPERIMENTAL): 50 mg Udenafil tablet plus 100 \& 150 mg placebo tablets
- Udenafil 100 mg (Type: EXPERIMENTAL): 100 mg Udenafil tablet plus 50 \& 150 mg placebo tablets
- Udenafil 150mg (Type: EXPERIMENTAL): 150 mg Udenafil tablet plus 50 \& 100 mg placebo tablets
- Placebo (Type: PLACEBO_COMPARATOR): 50, 100 \& 150 mg placebo tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Trazodone on the Severity of Obstructive Sleep Apnea in Insomnic Stroke Patients With Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Insomnic ischemic stroke patients with OSA and depression.~Exclusion Criteria:~* unclear consciousness, unstable vital sign or neurologic sign, unstable medical conditions such as delirium, active infection, evidence of overt congestive cardiac failure, liver dysfunction with ascites, thyroid disease, end-stage-renal-disease receiving dialysis.~* overnight mean oxygen saturation (SaO2) nadir is ≤ 70% at baseline~* take monoamine oxidase inhibitors (MAOI), any medication that may affect breathing, sleep, or muscle activity~* any known allergy to trazodone~* sleep disorder other than OSA (e.g., periodic leg movement syndrome, restless legs syndrome, central sleep apnea/Cheyne-Stokes respiration).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Trazodone (Type: ACTIVE_COMPARATOR): take trazodone 100mg hs
- Placebo (Type: PLACEBO_COMPARATOR): take placebo pill hs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ORAL T-6: Oral Androgens in Man-6

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* males between 18 to 50 years of age in good general health based on normal screening evaluation~* must agree not to participate in another research drug study during participation~* must agree to not donate blood during the study~* must be willing to comply with the study protocol and procedures~* must agree to use an acceptable form of contraception~* agrees to not take medications other than the study drugs for the duration of the study~Exclusion Criteria:~* Subject in poor health, determined by medical history physical and lab results~* a known history or current use of alcohol, drug or steroid abuse and/or use of more than 3 alcohol beverages per day~* Participation in a long-term contraceptive study within the past two months~* History of bleeding disorders or current use of anti-coagulants~* History of sleep apnea and/or major psychiatric disorders

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Oral testosterone (Type: EXPERIMENTAL): (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.
- Finasteride plus Oral Testosterone (Type: EXPERIMENTAL): (Day -2 to Day 12) 1 mg Finasteride PO once daily for 14 days total. (Day 1) Acyline 300 mcg/kg once, followed 24 hours later (Day 2) by immediate release T 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The ARIES HeartMate 3 Pump IDE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject will receive the HeartMate 3 per standard of care (SOC) in accordance with the approved indications for use in the country of implant.~2. Subject will receive the HeartMate 3 as their first durable VAD.~3. Subject must provide written informed consent prior to any clinical investigation related procedure.~4. In female patients of child bearing capability, subject will not be currently pregnant or breastfeeding and on appropriate contraception.~Exclusion Criteria:~1. Post-implant additional temporary or permanent mechanical circulatory support (MCS).~2. Investigator mandated antiplatelet therapy for other conditions (including mandated presence or absence of antiplatelet agent).~3. Patients who are nil per os (NPO) post-implant through day 7.~4. Subjects with a known allergy to acetylsalicylic acid (aspirin).~5. Participation in any other clinical investigation(s) involving an MCS device, or interventional investigation(s) likely to confound study results or affect study outcome.~6. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): LVAD Patients on the placebo arm will be given placebo medication
- Active Arm (Type: ACTIVE_COMPARATOR): LVAD Patients on the active arm will be given 100mg Aspirin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete